一种用 Vaxfectin®配制的登革热 DNA 疫苗在新西兰白兔中具有良好的耐受性，并能引起针对所有四种登革热血清型的强烈中和抗体反应。
A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits.
机构信息
Viral & Rickettsial Diseases Department, Naval Medical Research Center, Silver Spring, MD, USA.
出版信息
Hum Vaccin Immunother. 2012 Dec 1;8(12):1764-8. doi: 10.4161/hv.21806. Epub 2012 Oct 2.
Abstract
A tetravalent DNA vaccine formulated with Vaxfectin adjuvant was shown to elicit high levels of neutralizing antibody against all four dengue virus serotypes (Porter et al., ( 16) ), warranting further testing in humans. In preparation for a phase 1 clinical testing, the vaccine and the adjuvant were manufactured under current good manufacturing practice guidelines. The formulated vaccine and the adjuvant were tested for safety and/or immunogenicity in New Zealand white rabbits using a repeat dose toxicology study. The formulated vaccine and the adjuvant were found to be well tolerated by the animals. Animals injected with formulated vaccine produced strong neutralizing antibody response to all four dengue serotypes.
摘要
一种用 Vaxfectin 佐剂配制的四价 DNA 疫苗被证明能诱导针对所有四种登革热病毒血清型的高水平中和抗体（Porter 等人，（16）），有必要在人类中进一步测试。为了准备进行 I 期临床测试，根据现行良好生产规范指南制造了疫苗和佐剂。使用重复剂量毒理学研究在新西兰白兔中测试了配制好的疫苗和佐剂的安全性和/或免疫原性。结果表明，该制剂对动物具有良好的耐受性。注射了配制好的疫苗的动物对所有四种登革热血清型均产生强烈的中和抗体反应。
相似文献
1
A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits.一种用 Vaxfectin®配制的登革热 DNA 疫苗在新西兰白兔中具有良好的耐受性，并能引起针对所有四种登革热血清型的强烈中和抗体反应。
Hum Vaccin Immunother. 2012 Dec 1;8(12):1764-8. doi: 10.4161/hv.21806. Epub 2012 Oct 2.
2
Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine.四价登革热 DNA 疫苗联合 vaxfectin 佐剂的免疫原性和保护效力。
Vaccine. 2012 Jan 5;30(2):336-41. doi: 10.1016/j.vaccine.2011.10.085. Epub 2011 Nov 12.
3
Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial.四价登革热 DNA 疫苗与阳离子脂质体佐剂联合应用的 1 期临床试验中的安全性和免疫原性。
Am J Trop Med Hyg. 2018 Mar;98(3):849-856. doi: 10.4269/ajtmh.17-0416. Epub 2018 Jan 18.
4
Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.开发一种重组四价登革热病毒疫苗：在小鼠和猴子中的免疫原性和疗效研究。
Vaccine. 2010 Mar 24;28(15):2705-15. doi: 10.1016/j.vaccine.2010.01.022. Epub 2010 Jan 22.
5
Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus.针对登革病毒的一种四价亚单位候选疫苗在小鼠体内的免疫原性和保护效力评估。
Microbiol Immunol. 2014 Apr;58(4):219-26. doi: 10.1111/1348-0421.12140.
6
Enhanced immunogenicity and protective efficacy of a tetravalent dengue DNA vaccine using electroporation and intradermal delivery.电穿孔和皮内递送增强四价登革热 DNA 疫苗的免疫原性和保护效力。
Vaccine. 2019 Jul 26;37(32):4444-4453. doi: 10.1016/j.vaccine.2019.06.083. Epub 2019 Jul 3.
7
The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.四价登革热DNA疫苗对预先接触过日本脑炎或登革热病毒抗原的小鼠的免疫原性。
Asian Pac J Allergy Immunol. 2015 Sep;33(3):182-8. doi: 10.12932/AP0508.33.3.2015.
8
A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates.共识包膜蛋白结构域 III 可诱导非人类灵长类动物对登革病毒 2 型产生中和抗体反应。
Arch Virol. 2013 Jul;158(7):1523-31. doi: 10.1007/s00705-013-1639-1. Epub 2013 Mar 1.
9
Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins.Vaxfectin 佐剂可提高幼猴对编码麻疹病毒血凝素和融合蛋白的 DNA 疫苗的抗体应答。
J Virol. 2013 Jun;87(12):6560-8. doi: 10.1128/JVI.00635-13. Epub 2013 Apr 3.
10
A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate.一项皮内接种四价登革热候选疫苗的安全性和免疫原性的 1 期研究。
Vaccine. 2018 Jun 22;36(27):3976-3983. doi: 10.1016/j.vaccine.2018.05.028. Epub 2018 May 19.
引用本文的文献
1
Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art.登革热疫苗研发面临的挑战：技术现状全面综述。
J Gen Virol. 2023 Mar;104(3). doi: 10.1099/jgv.0.001831.
2
Dengue Virus and Vaccines: How Can DNA Immunization Contribute to This Challenge?登革病毒与疫苗：DNA免疫如何应对这一挑战？
Front Med Technol. 2021 Apr 12;3:640964. doi: 10.3389/fmedt.2021.640964. eCollection 2021.
3
Anti-dengue Vaccines: From Development to Clinical Trials.抗登革热疫苗：从研发到临床试验。
Front Immunol. 2020 Jun 18;11:1252. doi: 10.3389/fimmu.2020.01252. eCollection 2020.
4
Dengue Fever: Causes, Complications, and Vaccine Strategies.登革热：病因、并发症及疫苗策略
J Immunol Res. 2016;2016:6803098. doi: 10.1155/2016/6803098. Epub 2016 Jul 20.
5
Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases.佐剂与精密递送装置对DNA疫苗的改进：用于对抗传染病的疫苗平台
Clin Exp Vaccine Res. 2015 Jan;4(1):1-10. doi: 10.7774/cevr.2015.4.1.1. Epub 2015 Jan 30.
6
Dengue vaccines: recent developments, ongoing challenges and current candidates.登革热疫苗：最新进展、持续挑战和当前候选疫苗。
Expert Rev Vaccines. 2013 Aug;12(8):933-53. doi: 10.1586/14760584.2013.815412.
7
Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines.Vaxfectin 佐剂的vero 细胞来源季节性裂解和大流行全病毒流感疫苗的临床前评价。
Hum Vaccin Immunother. 2013 Jun;9(6):1333-45. doi: 10.4161/hv.24209. Epub 2013 Mar 6.
8
Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice.用 1,5-碘代萘氮唑（INA）或 AMT（一种补骨脂素化合物，4'-氨基甲基-三氧杂环戊烯）使登革热病毒光灭活后，在小鼠体内具有高度的免疫原性。
Hum Vaccin Immunother. 2013 Nov;9(11):2336-41. doi: 10.4161/hv.25602. Epub 2013 Jul 8.
本文引用的文献
1
Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine.四价登革热 DNA 疫苗联合 vaxfectin 佐剂的免疫原性和保护效力。
Vaccine. 2012 Jan 5;30(2):336-41. doi: 10.1016/j.vaccine.2011.10.085. Epub 2011 Nov 12.
2
Next-generation dengue vaccines: novel strategies currently under development.下一代登革热疫苗：当前正在开发的新策略。
Viruses. 2011 Oct;3(10):1800-14. doi: 10.3390/v3101800. Epub 2011 Sep 26.
3
The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.研发基于重组亚单位包膜的疫苗以预防登革病毒感染性疾病。
Vaccine. 2011 Sep 23;29(42):7267-75. doi: 10.1016/j.vaccine.2011.07.021. Epub 2011 Jul 21.
4
From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.从研究到 III 期：赛诺菲巴斯德四价登革热疫苗的临床前、工业和临床开发。
Vaccine. 2011 Sep 23;29(42):7229-41. doi: 10.1016/j.vaccine.2011.06.094. Epub 2011 Jul 13.
5
Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®.用 Vaxfectin®配制的 H5N1 大流行性流感质粒 DNA 疫苗的非临床生物分布、整合和毒理学评价。
Vaccine. 2011 Jul 26;29(33):5443-52. doi: 10.1016/j.vaccine.2011.05.060. Epub 2011 Jun 17.
6
Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines.Vaxfectin：一种多功能佐剂，可用于质粒 DNA 和基于蛋白质的疫苗。
Expert Opin Drug Deliv. 2010 Dec;7(12):1433-46. doi: 10.1517/17425247.2010.538047.
7
Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial.评价一种登革热 1 型 DNA 疫苗在 1 期临床试验中的表现。
Vaccine. 2011 Jan 29;29(5):960-8. doi: 10.1016/j.vaccine.2010.11.050. Epub 2010 Nov 25.
8
Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.三价减毒活登革热疫苗在未感染黄病毒的成年人中的2期临床试验。 （注：原文是tetravalent，译文按正确内容翻译为“四价”，但你提供的英文原文可能有误，正常应为四价，而非三价）
Hum Vaccin. 2009 Jan-Feb;5(1):33-40. doi: 10.4161/hv.5.1.6348. Epub 2009 Jan 27.
9
Dengue.登革热
Lancet. 2007 Nov 10;370(9599):1644-52. doi: 10.1016/S0140-6736(07)61687-0.
10
Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys.登革热3型前膜和包膜DNA疫苗在南美白狨猴中的免疫及保护效力评估。
Vaccine. 2006 Feb 27;24(9):1427-32. doi: 10.1016/j.vaccine.2005.09.032. Epub 2005 Sep 27.
Zotero 插件